Merck and the Canadian Cancer Trials Group (CCTG) have reported positive data from the Phase II/III CCTG IND.227/KEYNOTE-483 trial of Keytruda, along with chemotherapy, as first-line treatment for advanced malignant pleural mesothelioma patients. The open-label, randomised Phase II/III trial has been designed for assessing the combination of … [Read more...]
Does the Presence of Asbestos-Containing Materials in Buildings Post-construction and Before Demolition Have an Impact on the Exposure to Occupants in Non-occupational Settings?
Abstract This narrative review aims to determine if asbestos-containing materials in buildings pose a hazard to building occupants in non-occupational settings. This paper is limited to the post-construction and pre-demolition stages of a building. The researchers selected 19 studies from the 126 studies screened, concerning exposure to asbestos … [Read more...]
Prolia Side Effect: Hypocalcemia in Patients on Dialysis
This relatively new Prolia side effect, hypocalcemia, first came to our attention in late 2022 with the release of this November 22, 2022 document, “FDA Drug Safety Communication: FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)”. From that November 2022 FDA Drug Safety … [Read more...]
Incidence of Malignant Pleural Mesothelioma Decreased in the United States During 2004 to 2019
Despite a rising global incidence, long-term data reveal the U.S. [ incidence rate of pleural mesothelioma ] has decreased and overall survival for patients with mesothelioma is improving, according to a study presented at the annual meeting of the European Lung Cancer Congress, held from March 29 to April 1 in Copenhagen, Denmark. Mohamed … [Read more...]
EzriCare Artificial Tears Case Reports Involving Vision Loss
A recent edition of the JAMA Ophthalmology medical journal presented two EzriCare Artificial Tears case reports about serious infection and vision loss associated with these over-the-counter (OTC) eye drops from Global Pharma. The two EzriCare Artificial Tears case reports are set forth in these March 2023 JAMA Ophthalmology medical journal … [Read more...]
EPA Asks for More Public Input on Asbestos After ProPublica and Others Reveal New Information
The Environmental Protection Agency took an unusual step last week: It opened a new period in which the public can comment on its proposed asbestos ban. The agency had gotten new information, officials said, including a series of ProPublica reports on dangerous working conditions in factories that use asbestos to make chlorine. Asbestos has been … [Read more...]
Breast Implant-Associated Lymphoma: PROFILE Registry; Update on Number of Cases
From this recent FDA Safety Communication "UPDATE: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants" we get the following information about the new reporting system for cases of breast implant-associated lymphoma -- the shorthand term for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): As of March … [Read more...]
A Gelatinous Pleural Effusion as a Diagnostic Clue
Pleural effusion is a common presentation of several pathologies, and the determination of its cause is facilitated by macroscopic, biochemical, microbiological, and cellular analysis. A systematic approach to analyzing the fluid allows for a reduction in clinical diagnoses. Only a select number of diagnoses can be established definitively by … [Read more...]
Firefighter Protective Gear Made With Toxic Chemicals PFAS
Firefighter bunker gear and turnout gear -- the uniforms worn by firemen when going out to fight a fire -- contain per- and polyfluoroalkyl substances (PFAS), a highly toxic class of chemicals. Here are two important facts from a February 2021 article, "Firefighters face lies, ‘phony’ studies on PFAS exposure": All protective firefighting … [Read more...]
EzriCare and Delsam Products Recall: March 2023 Update
Here is the most recent information from the US Centers for Disease Control and Prevention (CDC) about the EzriCare and Delsam products recall for case reports associated with bacterial contamination: As of March 1, 2023, CDC, in partnership with state and local health departments, identified 64 patients in 13 states (CA, CO, CT, FL, IL, NJ, NM, … [Read more...]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 20
- Next Page »